ISSN: 0443-511
e-ISSN: 2448-5667
Usuario/a
Idioma
Herramientas del artículo
Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión)
Tamaño de fuente

Open Journal Systems

Infarto agudo al miocardio con elevación del segmento ST en época de COVID-19

Mario Alberto García-Esquivel, Fernando Huerta-Liceaga, Luis Alexander Martínez-Garzón, Rafael Alan Sandoval-Espadas, Latife Salame-Khouri

Resumen


La infección por coronavirus SARS-CoV-2 es una emergencia sanitaria global que puede afectar gravemente a las personas cardiópatas. En condiciones normales, los pacientes que se presentan en las unidades médicas con diagnóstico de infarto agudo al miocardio con elevación del segmento ST (IAM-CEST) deben ser atendidos con estrategia de reperfusión coronaria de manera urgente. Sin embargo, no existen lineamientos bien establecidos sobre el tratamiento de los pacientes con IAM-CEST y COVID-19 debido a la aún escasa información al respecto, dada la súbita aparición de la enfermedad. En este artículo se exponen los principales aspectos de los artículos más relevantes sobre el manejo del IAM-CEST en el contexto de esta pandemia. El objetivo de esta publicación es apoyar en la toma de decisiones para el manejo del IAM-CEST en el contexto de la emergencia por COVID-19.


Palabras clave


Infarto del Miocardio con Elevación del ST; Infecciones por Coronavirus; Intervención Coronaria Percutánea; Terapia Trombolítica

Texto completo:

PDF HTML

Referencias


Guan WJ, Ni ZY, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-20. DOI: 10.1056/NEJMoa2002032.

 

Rabi F, Al Zoubi M, Kasasbeh G, Salameh DM, Al-Nasser AD. SARS-CoV-2 and Coronavirus Disease 2019: what we know so far. Pathogens. 2020;9(3): 231. DOI:10.3390/pathogens9030231.

 

Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting Enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4): 586-590. DOI: 10.1007/s00134-020-05985-9.

 

Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020;41 (19):1798-1800. DOI: 10.1093/eurheartj/ ehaa231.

 

Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109:531-8. DOI: 10.1007/ s00392-020-01626-9.

 

Prabakaran P, Xiao X, Dimitrov D. A model of the ACE2 structure and function as a SARS-CoV receptor. Biochem Biophys Res Commun. 2004; 314(1):235-41. DOI: 10.1016/j.bbrc.2003.12.081.

 

Chen D, Li X, Song Q, et al. Assessment of hypokalemia and clinical characteristics in patients with coronavirus disease 2019 in Wenzhou, China. JAMA Netw Open. 2020;3(6):e2011122. DOI: 10.1001/jamanetworkopen.2020.11122.

 

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease Control and prevention. JAMA. 2020;323 (13):1239-1242. DOI: 10.1001/jama.2020.2648.

 

The World Health Organization. Coronavirus disease (COVID-19) situation reports. Ginebra, Suiza: WHO; 2020. Disponible en: https://www. who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/?gclid=Cj0KCQjwz4z3BRcgARIs AES_OVe0WaFxgoLFq6cYthBOQhvNm_5Bz_sqWxmFnShgTl-5kRApw5zAR-MaAg8bEALw_wcB

 

Departamento de Salud Pública de la Facultad de Medicina de la UNAM. Boletín sobre COVID-19, salud pública y epidemiología. 2020;1(3). Disponible en: http://dsp.facmed.unam.mx/wp-content/uploads/2013/ 12/COVID-19-No.3-00-Bolet%C3%ADn-completo.pdf

 

Instituto Nacional de Estadística, Geografía e Informática (INEGI). Indicadores Sociodemográfícos en la República Mexicana 2018. Ciudad de México, México: INEGI; 2019. Disponible en: https://www.inegi.org.mx/app/indicadores/?ind=6204482262&tm= 6#divFV6204482233#D6204482262

 

The World Health Organization. Mortality Data Base. Ginebra, Suiza: WHO; 2019. Disponible en: https://www.who.int/healthinfo/mortality_data/en/

 

Mittleman MA, Mostofsky E. Physical, psychological and chemical triggers of acute cardiovascular events: Preventive strategies. Circulation. 2011;124(3):346-54. DOI: 10.1161/ CIRCULATIONAHA.110.968776.

 

Dimsdale JE. Psychological stress and cardiovascular disease. J Am Coll Cardiol. 2008;51(13):1237-46. DOI: 10.1016/j.jacc.2007.12.024.

 

Madjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV, et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: Results from 8 years of autopsies in 34 892 subjects. Eur Heart J. 2007;28(10):1205-10. DOI: 10.1093/eurheartj/ehm035.

 

Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Carnauchow T, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018;378(4):345-353. DOI: 10.1056/NEJMoa1702090.

 

Blackburn RM, Zhao H, Pebody R, Hayward A, Warren-Gash C. Laboratory-confirmed respiratory infections as predictors of hospital admission for myocardial infarction and stroke: time-series analysis of English data for 2004–2015. Clin Infect Dis. 2018;67:8-17. DOI: 10.1093/cid/cix1144.

 

Rodríguez-Leora O, Cid-Álvarez B, Ojeda S, Martín-Moreiras J, Rumoroso JR, López-Palop R, et al. Impacto de la pandemia de COVID-19 sobre la actividad asistencial en cardiología intervencionista en España. REC Interv Cardiol. 2020;2:82-89. DOI: https://doi.org/10.24875/ RECIC.M20000120

 

Garcia S, Albaghdadi MS, Meraj PM, Schmidt C, Garberich R, Jaffer FA, et al. Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic. J Am Coll Cardiol. 2020;75 (22):2871-2872. DOI: 10.1016/j.jacc.2020.04.011.

 

Metzler B, Siostrzonek P, Binder RK, Bauer A, Reinstadler SJ. Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage. Eur Heart J. 2020;41 (19):1852-1853. DOI: 10.1093/eurheartj/ehaa314.

 

Tam C-CF, Cheung KS, Lam S, Wong A, Yung A, Sze M, et al. Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China. Circ Cardiovasc Qual Outcomes. 2020;13(4): e006631. DOI: 10.1161/CIRCOUTCOMES.120.006631.

 

Piña-Reyna Y, García-Rincón A, Ortiz-Fernández PH, Alcocer-Gamba MA, Gutiérrez-Fajardo P, Merino-Rajme JA, et al. Atención de la cardiopatía isquémica en salas de cateterismo durante la contingencia sanitaria por pandemia de COVID-19. Recomendaciones de la Sociedad de Cardiología Intervencionista de México (SOCIME). REC Interv Cardiol. 2020. DOI: https://doi.org/10.24875/RECIC. M20000123

 

Mahmud E, Dauerman HL, Welt FGP, Messenger JC, Rao SV, Grines C, et al. Management of acute myocardial infarction during the COVID-19 pandemic: a consensus statement from the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). Catheter Cardiovasc Interv. 2020. doi: 10.1002/ccd.28946.

 

Romaguera R, Cruz-González I, Ojeda S, Jiménez-Candil J, Calvo D, García-Seara J, et al. Consideraciones sobre el abordaje invasivo de la cardiopatía isquémica y estructural durante el brote de coronavirus COVID-19. Documento de consenso de la Asociación de Cardiología Intervencionista y la Asociación de Cardiopatía Isquémica de la Sociedad Española de Cardiología. REC Interv Cardiol. 2020; 2: 106-111. DOI: https://doi.org/10.24875/RECICE. M20000116

 

Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment Elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment wlevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177. DOI: 10.1093/eurheartj/ehx393.

 

Beitzke D, Salgado R, Francone M, Kreitner KF, Natale L, Bremerich J, et al. Cardiac imaging procedures and the COVID-19 Pandemic: recommendations of the European Society of Cardiovascular Radiology (ESCR). Int J Cardiovasc Imaging. 2020;1-10. DOI: 10.1007/ s10554-020-01892-8.

 

Roe MT, Messenger JC, Weintraub WS, Cannon CP, Fonarow GC, Dai D, et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol. 2010;56:254-263. DOI: 10.1016/j.jacc.2010.05.008.

 

Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368:1379-1387. DOI: 10.1056/NEJMoa1301092.

 

Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol. 2003;92:824-826. DOI: 10.1016/ s0002-9149(03)00891-9

 

Jing ZC, Zhu HD, Yan XW, Chai WZ. Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak. Eur Heart J. 2020;41(19):1791-1794. DOI: 10.1093/ eurheartj/ehaa258.

 

Daniels MJ, Cohen MG, Bavry AA, Kumbhani DJ. Reperfusion of STEMI in the COVID-19 Era - Business as Usual? Circulation. 2020;141:1948-1950. DOI: 10.1161/ CIRCULATIONAHA.120.047122.

 

European Society of Cardiology. ESC Guidance for the diagnosis and management of CV disease during the COVID-19 pandemic. Sophia Antipolis, France: ESC; 2020. Disponible en: https://www. escardio.org/Education/COVID-19-and-Cardiology/ ESC-COVID-19-Guidance

 

Han Y, Zeng H, Jiang H, Yang Y, Yuan Z, Cheng X, et al. CSC Expert Consensus on principles of clinical management of patients with severe emergent cardiovascular diseases during the COVID-19 epidemic. Circulation. 2020;141:e810-e816. DOI: 10.1161/CIRCULATIONAHA.120.047011

 

National Health Committee of People's Republic of China. Regulation for prevention and control of healthcare associated infection of airborne transmission disease in healthcare facilities. Beijing, China: NHCPRC; 2016. Disponible en: http://en.nhc.gov.cn/index.html

 

World Health Organization. Infection prevention and control during health care when COVID-19 is suspected. Ginebra, Suiza: WHO; 2020. Disponible en: https://www.who.int/publications/i/item/10665-331495

 

National Health Committee of the People's Republic of China. Basic Rules on infection prevention and control in medical institution (Trial Edition). Beijing, China: NHCPRC; 2019. Disponible en: http://en.nhc.gov.cn/index.html

 

National Health Committee of the People's Republic of China. Chinese Clinical guideline for COVID-19 diagnosis and treatment (5th Edition). Beijing, China: NHCPRC; 2020. Disponible en: http://en.nhc.gov.cn/index.html

 

Yang Q, Liu Q, Xu H, Lu H, Liu S, Li H. Imaging of Coronavirus Disease 2019: A Chinese Expert Consensus Statement. Eur J Radiol. 2020;127: 109008. https://doi.org/10.1016/j.ejrad.2020.109008

 

van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson B, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020; 382:1564-1567. DOI: 10.1056/NEJMc2004973. 


Enlaces refback

  • No hay ningún enlace refback.